Pulmonary Therapy最新文献

{"title":"Triple Therapy with Mometasone/Indacaterol/Glycopyrronium or Doubling the ICS/LABA Dose in GINA Step 4: IRIDIUM Analyses.","authors":"Richard N van Zyl-Smit, Huib A M Kerstjens, Jorge Maspero, Ana-Maria Tanase, David Lawrence, Karen Mezzi, Peter D'Andrea, Kenneth R Chapman","doi":"10.1007/s41030-023-00234-y","DOIUrl":"10.1007/s41030-023-00234-y","url":null,"abstract":"<p><strong>Introduction: </strong>GINA guidelines recommend increasing the dose of inhaled corticosteroids (ICS) as a step-up option for patients with inadequately controlled asthma at GINA step 4 [inadequately controlled asthma on medium-dose ICS/long-acting beta-2 agonist (LABA)]. The aim of this study was to compare the efficacy and safety of long-acting muscarinic antagonists (LAMA) add-on to medium-dose ICS/LABA in patients at GINA 2022 step 4.</p><p><strong>Methods: </strong>This post hoc analysis of the IRIDIUM study evaluated the change from baseline in trough forced expiratory volume (FEV₁ ) in patients receiving medium-dose MF/IND/GLY versus high-dose MF/IND and high-dose FLU/SAL at Week 26. Other outcomes included improvement in lung functions [peak expiratory flow (PEF), forced vital capacity (FVC), forced expiratory flow between 25% and 75% of the FVC (FEF)_25-75%)], asthma control [Asthma Control Questionnaire (ACQ-7)], responder analysis (≥ 0.5 unit improvement in ACQ-7), and reduction in asthma exacerbations at Weeks 26 and 52.</p><p><strong>Results: </strong>A total of 1930 patients were included in this analysis. Medium-dose MF/IND/GLY improved trough FEV₁ versus high-dose MF/IND (Δ 41 mL; 95% CI - 7-90) and high-dose FLU/SAL (Δ 88 mL; 95% CI 39-137) at Week 26 which were sustained until Week 52. Exacerbation rates were 16% lower with medium-dose MF/IND/GLY versus high-dose MF/IND for all (mild, moderate, and severe) exacerbations and 21-30% lower versus high-dose FLU/SAL for all (mild, moderate, and severe), moderate or severe, and severe exacerbations over 52 weeks. Further improvements in other lung functions were observed with medium-dose MF/IND/GLY. No new safety signals were identified.</p><p><strong>Conclusion: </strong>Medium-dose MF/IND/GLY improved lung function and reduced asthma exacerbations compared to high-dose ICS/LABA and may be an undervalued option in patients at GINA 2022 step 4.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT02571777.</p>","PeriodicalId":20919,"journal":{"name":"Pulmonary Therapy","volume":"9 3","pages":"395-409"},"PeriodicalIF":3.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0b/87/41030_2023_Article_234.PMC10447675.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10061295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gaps and Future Directions in Clinical Research on Obesity-Related Asthma.","authors":"Andi C Hudler, Isaías Raymundo Ramírez Díaz, Sunita Sharma, Fernando Holguin","doi":"10.1007/s41030-023-00230-2","DOIUrl":"10.1007/s41030-023-00230-2","url":null,"abstract":"<p><p>Obesity is a major comorbidity for the development and worsening of asthma. It is associated with increased disease incidence, reduced response to inhaled and systemic steroids, increased asthma exacerbations, and poor disease control. Over the past two decades, we have learned that there are clinical asthma phenotypes associated with obesity, which have unique immune, inflammatory, and metabolic disease mechanisms. The objectives of this review are to provide a brief overview of the associations and gaps between these chronic inflammatory diseases and the role that traditional therapies have on treating patients with obesity-related asthma, and to describe new clinical research of therapeutic developments targeting mechanisms that are more specific to this patient population.</p>","PeriodicalId":20919,"journal":{"name":"Pulmonary Therapy","volume":"9 3","pages":"309-327"},"PeriodicalIF":3.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/84/ef/41030_2023_Article_230.PMC10447703.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10067859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis: A Narrative Review.","authors":"Hana Alsomali,&nbsp;Evelyn Palmer,&nbsp;Avinash Aujayeb,&nbsp;Wendy Funston","doi":"10.1007/s41030-023-00216-0","DOIUrl":"https://doi.org/10.1007/s41030-023-00216-0","url":null,"abstract":"<p><p>Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrosing interstitial lung disease of unknown aetiology. Patients typically present with symptoms of chronic dyspnoea and cough over a period of months to years. IPF has a poor prognosis, with an average life expectancy of 3-5 years from diagnosis if left untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been approved for the treatment of IPF. These drugs slow disease progression by reducing decline in lung function. Early diagnosis is crucial to ensure timely treatment selection and improve outcomes. High-resolution computed tomography (HRCT) plays a major role in the diagnosis of IPF. In this narrative review, we discuss the importance of early diagnosis, awareness among primary care physicians, lung cancer screening programmes and early IPF detection, and barriers to accessing anti-fibrotic medications.</p>","PeriodicalId":20919,"journal":{"name":"Pulmonary Therapy","volume":"9 2","pages":"177-193"},"PeriodicalIF":3.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d1/ff/41030_2023_Article_216.PMC10203082.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9907995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Engaging Ethnically Diverse Populations in Self-Management Interventions for Chronic Respiratory Diseases: A Narrative Review.","authors":"Stacy Maddocks,&nbsp;Pat Camp,&nbsp;Clarice Tang","doi":"10.1007/s41030-023-00218-y","DOIUrl":"https://doi.org/10.1007/s41030-023-00218-y","url":null,"abstract":"<p><p>The burden of chronic respiratory diseases continues to rise globally. Comprehensive management relies on a combination of treatment approaches including patient self-management, where health professionals are required to educate and support patients to take control of their disease. When self-management interventions are suitably directed and effectively executed, outcomes point to increases in quality of life and a reduction in unscheduled or emergency consultations for people living with chronic respiratory disease. However, despite these positive gains, the literature reveals poor trends of engagement with this management approach and reduced access to appropriately designed programs for people from ethnically diverse populations, including migrants and refugees. The purpose of this review article is to discuss factors influencing engagement in chronic respiratory disease self-management among people from ethnically diverse backgrounds and to propose strategies to improve the participation of this population in these interventions in the future.</p>","PeriodicalId":20919,"journal":{"name":"Pulmonary Therapy","volume":"9 2","pages":"195-206"},"PeriodicalIF":3.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7a/93/41030_2023_Article_218.PMC9922039.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9766012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Results From a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis.","authors":"Mehdi Mirsaeidi,&nbsp;Robert P Baughman,&nbsp;Debasis Sahoo,&nbsp;Eva Tarau","doi":"10.1007/s41030-023-00222-2","DOIUrl":"https://doi.org/10.1007/s41030-023-00222-2","url":null,"abstract":"<p><strong>Introduction: </strong>Long-term treatment of pulmonary sarcoidosis with glucocorticoids has been associated with toxicity and other adverse events, highlighting the need for alternative therapies. The goal of this study was to evaluate the efficacy and safety of repository corticotropin injection (RCI, Acthar^® Gel) in patients with pulmonary sarcoidosis and to validate endpoints for use in future clinical trials.</p><p><strong>Methods: </strong>In this multicenter, randomized, placebo-controlled trial, subjects received subcutaneous RCI (80 U) twice weekly or matching placebo through 24 weeks in a double-blind treatment phase, followed by an optional 24-week open-label extension. Efficacy was measured by glucocorticoid tapering, pulmonary function tests, chest imaging, patient-reported outcomes, and a novel sarcoidosis treatment score (STS). Safety was assessed by adverse events, physical examinations, vital signs, clinical laboratory abnormalities, and imaging. The study was terminated early due to low enrollment caused by the COVID-19 pandemic, thereby precluding statistical analysis.</p><p><strong>Results: </strong>Fifty-five subjects were randomized to receive either RCI (n = 27) or placebo (n = 28). Mean STS at week 24 showed greater improvement with RCI (1.4) compared with placebo (0.7). At week 48, those who remained on RCI had an STS of 1.8 compared with 0.9 in those who switched from placebo to RCI. More subjects in the RCI group discontinued glucocorticoids at week 24 compared to the placebo group. Glucocorticoid discontinuation was comparable at week 48 for those who switched from placebo to RCI and those who continued RCI. Similar trends in favor of RCI over placebo were observed with the other efficacy endpoints. No new or unexpected safety signals were identified.</p><p><strong>Conclusions: </strong>RCI was safe and well tolerated, with trends in efficacy data suggesting greater improvement with RCI compared to placebo in patients receiving standard-of-care therapy for pulmonary sarcoidosis. The study also provided validation of efficacy endpoints that may be used in larger trials for pulmonary sarcoidosis.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifier: NCT03320070.</p>","PeriodicalId":20919,"journal":{"name":"Pulmonary Therapy","volume":"9 2","pages":"237-253"},"PeriodicalIF":3.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/aa/87/41030_2023_Article_222.PMC10113127.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9825478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Giant Tracheal Fibroepithelial Polyp Treated Successfully by High-Frequency Electrocautery Ablation.","authors":"Cong Nguyen-Hai,&nbsp;Thien Vo-Nguyen-Thuan,&nbsp;Thang Tran-Quyet,&nbsp;Sy Duong-Quy","doi":"10.1007/s41030-023-00223-1","DOIUrl":"https://doi.org/10.1007/s41030-023-00223-1","url":null,"abstract":"<p><p>Endotracheal fibroepithelial polyp is a rare disease in the airways. This report describes a rare case of a tracheal giant fibroepithelial polyp. A 17-year-old woman was admitted to the hospital with severe acute respiratory failure. Chest computed tomography revealed a tumor located below the epiglottis. Endotracheal bronchoscopic examination showed a giant polyp. This endotracheal polyp was removed with ablation, by using high-frequency electricity through flexible bronchoscopy under intravenous anesthesia. The patient has had a good recovery after the intervention and at long-term follow-up. We herein describe and discuss the appropriate therapeutic approach and also review the pertinent literature.</p>","PeriodicalId":20919,"journal":{"name":"Pulmonary Therapy","volume":"9 2","pages":"281-286"},"PeriodicalIF":3.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/60/7d/41030_2023_Article_223.PMC10203072.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9770369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Long-Term Oxygen Therapy on Reducing Rehospitalization of Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis.","authors":"Ramin Sami,&nbsp;Mahsa Akafzadeh Savari,&nbsp;Marjan Mansourian,&nbsp;Roghayeh Ghazavi,&nbsp;Rokhsareh Meamar","doi":"10.1007/s41030-023-00221-3","DOIUrl":"https://doi.org/10.1007/s41030-023-00221-3","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of this work is to evaluate whether the addition of home oxygen therapy (HOT) would reduce readmission in chronic obstructive pulmonary disease (COPD) patients.</p><p><strong>Methods: </strong>PubMed, ScopeMed, Cochrane, Scopus, and Google Scholar databases were searched. The search strategy used the following keywords \"chronic obstructive pulmonary disease\", the intervention \"long-term oxygen therapy\", and the outcome \"readmission\" combined with the AND operator. The Newcastle-Ottawa Scale and Jadad Scale were used for assessing the quality of cohort studies and clinical trials, respectively. A random-effects model was employed in this study after calculating the standard errors by 95% confidence intervals. The I2 statistic and Cochran's Q-test were used to measure heterogeneity. To address heterogeneity, subgroup analyses were carried out according to the length of LTOT, which was classified as \"over 8 months\" and \"under 8 months\".</p><p><strong>Results: </strong>Seven studies were included in the analysis. In the pooled analysis, the RR [CI95%, p value], heterogeneity criteria for readmission reduced by 1.542 [1.284-1.851, < 0.001], I² = 60%, and 1.693 [1.645-1.744, < 0.001], I² = 60% for patients with a length of LTOT treatment under and above 8 months, respectively. A sensitivity analysis was conducted by systematically omitting each study, and it showed no influential studies. Egger's test indicated no publication bias (p = 0.64).</p><p><strong>Conclusions: </strong>Based on our results in this systematic review, long-tern oxygen therapy (LTOT) at home was associated with a significantly lower risk ratio of hospital readmission. However, the sample sizes in the studies necessitate larger RCTs to evaluate the effect of LTOT on readmission in COPD patients.</p>","PeriodicalId":20919,"journal":{"name":"Pulmonary Therapy","volume":"9 2","pages":"255-270"},"PeriodicalIF":3.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/77/ac/41030_2023_Article_221.PMC10203089.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9769049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Famotidine on COVID-19: Killing Virus or Opposing ARDS?","authors":"Mahnaz Sadat Hosseini,&nbsp;Effat Davoudi-Monfared,&nbsp;Farhad Najmeddin,&nbsp;Mojtaba Mojtahedzadeh","doi":"10.1007/s41030-023-00220-4","DOIUrl":"https://doi.org/10.1007/s41030-023-00220-4","url":null,"abstract":"<p><p>Since the first detection of SARS-CoV-2 in China, COVID-19 (Corona Virus Disease 2019) has taken the lives of more than six million people. Although some antivirals seem proper for treatment, the investigation of finding the best therapeutic approach for COVID-19 is still continuing. Some observational research showed that famotidine has promising effects in addition to its acid-suppressing characteristics in the treatment of COVID-19. The definite viricidal effect of famotidine is not established. Opposing acute respiratory distress syndrome (ARDS) can be proposed as a probable mechanism for the action of famotidine, due to its inhibitory effect on histamine release, inhibition of transmembrane protease serine S (TMPRSS) and stabilizing glycocalyx. These hypotheses should be under investigation in the future.</p>","PeriodicalId":20919,"journal":{"name":"Pulmonary Therapy","volume":"9 2","pages":"173-175"},"PeriodicalIF":3.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0d/a5/41030_2023_Article_220.PMC10066957.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9770352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Significance of Obstructive Sleep Apnea in a Population of Subjects with Interstitial Lung Diseases.","authors":"Debora Valecchi,&nbsp;Elena Bargagli,&nbsp;Maria Grazia Pieroni,&nbsp;Metella Rosa Refini,&nbsp;Piersante Sestini,&nbsp;Paola Rottoli,&nbsp;Andrea S Melani","doi":"10.1007/s41030-023-00215-1","DOIUrl":"https://doi.org/10.1007/s41030-023-00215-1","url":null,"abstract":"<p><strong>Introduction: </strong>Obstructive sleep apnea (OSA) is often observed in subjects with interstitial lung disease (ILD). It may have a negative impact on the course of ILD, but its prognostic significance in relation to other known indicators of poor outcome is unclear.</p><p><strong>Methods: </strong>After a detailed work-up, including overnight unattended type III polygraphy, all subjects newly diagnosed with ILDs referred to our clinics were followed-up for at least 1.5 years or until death or progression of disease [> 10% decline in forced vital capacity (FVC) below baseline]. We analyzed relationships between some prespecified variables of interest, including sleeping results, to establish parameters predictive of progressive course.</p><p><strong>Results: </strong>Our population consisted of 46 subjects (mean age 59.6 years; males 61%); 23.9% and 41% had idiopathic pulmonary fibrosis and ILD associated with systemic diseases, respectively. Mean baseline forced vital capacity and diffusion capacity of carbon monoxide were 83% and 57% of predicted, respectively. Mean (± SE) Apnea-Hypopnea Index (AHI) was 17 (± 3) events/h. AHI in the ranges 5-14.9, 15-29.9, and ≥ 30 was recorded in 14 (31%), 6 (13%), and 9 (20%) subjects, respectively. Mean distance covered in the 6-MWG walk test (6MWT) was 302 (± 19) m and 26 subjects (57%) showed exertional oxyhemoglobin desaturation. The median follow-up was about 18 months. Multivariate logistic regression analysis showed that exertional desaturation (HR 8.2; 1.8-36.5 95% CI; p = 0.006) and AHI ≥ 30, namely the threshold of severe OSA (HR 7.5; 1.8-30.6; p = 0.005), were the only independent variables related to progressive disease course.</p><p><strong>Conclusion: </strong>We conclude that exertional desaturation and elevated AHI had independent negative prognostic significance in our ILD population.</p>","PeriodicalId":20919,"journal":{"name":"Pulmonary Therapy","volume":"9 2","pages":"223-236"},"PeriodicalIF":3.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a1/87/41030_2023_Article_215.PMC10203065.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9759817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-COVID-19 Pulmonary Alveolar Proteinosis Treated Successfully with Whole Lung Lavage: A Rare Case Report.","authors":"Bao Le-Khac,&nbsp;Quoc-Khanh Tran-Le,&nbsp;Lam Nguyen-Ho,&nbsp;Sy Duong-Quy","doi":"10.1007/s41030-023-00224-0","DOIUrl":"https://doi.org/10.1007/s41030-023-00224-0","url":null,"abstract":"<p><p>Pulmonary alveolar proteinosis (PAP) is an uncommon disease and its diagnosis remains challenging. During the COVID-19 pandemic, it has been difficult to distinguish between PAP and post-COVID-19 pulmonary sequelae. Here we present a case of a 44-year-old male patient who experienced exertional dyspnea after recovering from COVID-19. He was initially diagnosed with post-COVID-19 syndrome and treated with systemic corticosteroid without improvement. Chest computed tomography (CT) showed crazy-paving pattern with ground-glass opacities. Fibreoptic bronchoscopy with bronchial lavage fluid (BLF) analysis confirmed the final diagnosis of PAP. The patient underwent left lung lavage in combination with conventional therapy and experienced significant improvement in his respiratory condition and overall health during follow-up. Hence, PAP could occur after a COVID-19 infection. This case highlights the importance of considering PAP as a potential diagnosis in patients with persistent respiratory symptoms after COVID-19. The high suspicion indicators of PAP revealed by chest-CT and BLF may be a key to differentiating PAP from post-COVID-19 pulmonary sequelae. Moreover, it is plausible that SARS-CoV-2 plays a role in the development of proteinosis, either by inducing a flare-up or by directly causing the condition.</p>","PeriodicalId":20919,"journal":{"name":"Pulmonary Therapy","volume":"9 2","pages":"287-293"},"PeriodicalIF":3.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/43/3e/41030_2023_Article_224.PMC10173208.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9770373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}